Hikma | Jotup

Collegium Reports First Quarter 2024 Financial Results

Retrieved on:

Thursday, May 9, 2024

Debt-to-GDP ratio, American Academy, Annual general meeting, Conference, Shareholder, AAPM, Interim, Adjustment, Hikma, Prescription, Note

ET –

Key Points:

ET –
STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter ended March 31, 2024, and provided a corporate update.
“Thanks to our dedicated team and successful first quarter, Collegium is progressing towards another year of record financial performance,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium.
I am confident the organization is well positioned to deliver on its financial and capital deployment priorities in 2024 by focusing on operational execution.”
“We delivered strong first quarter results marked by record Belbuca revenue, managed expenses and robust cash flows, positioning us to achieve our 2024 financial guidance,” said Colleen Tupper, Chief Financial Officer of Collegium.
Achieved Xtampza® ER gross-to-net of 53.6% in the quarter ended March 31, 2024.

Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform

Retrieved on:

Thursday, March 7, 2024

Dai, Hikma, Internet, Biotechnology, Mizuho Bank, Investment, Patient, Dai-ichi Life, SBI Group, Pharmaceutical industry

I would like to thank our many investors for having valued our achievements and great potential.

Key Points:

I would like to thank our many investors for having valued our achievements and great potential.
Rakuten Medical also welcomed Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA region, to its Board of Directors.
Darwazah is an experienced executive with more than 38 years of pharmaceutical industry experience gained through serving in various positions within the Hikma Group.
In making this investment and appointment to the Board of Directors, Darwazah commented, "I am honoured to join Rakuten Medical's board.

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Retrieved on:

Monday, January 8, 2024

The partnership expands Guardant Health’s global presence and includes products across the cancer care continuum.

Key Points:

The partnership expands Guardant Health’s global presence and includes products across the cancer care continuum.
The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
“We are committed to improving patient outcomes globally by offering next-generation sequencing tests across all stages of the disease.
We are excited to partner with Guardant Health, as their offering can help patients at all stages of the disease – from screening to monitoring cancer recurrence to guiding treatment decisions.

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Retrieved on:

Monday, January 8, 2024

Helmy Eltoukhy, Oncology, Immunotherapy, NGS, Partnership, Medicine, Hope, Disease, Hikma, Recurrence, Cancer, PALO, Patient, Medical imaging

The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.

Key Points:

The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
This agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in a majority of countries in the MENA region.
Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.
Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable."

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Retrieved on:

Monday, January 8, 2024

Helmy Eltoukhy, Oncology, Immunotherapy, NGS, Partnership, Medicine, Hope, Disease, Hikma, Recurrence, Cancer, PALO, Patient, Medical imaging

The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.

Key Points:

The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
This agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in a majority of countries in the MENA region.
Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.
Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable."

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

Retrieved on:

Tuesday, October 3, 2023

Tragedy Assistance Program for Survivors, The Washington Post, White House, Partnership, Naloxone, Office of National Drug Control Policy, State government, Medicine, School, Community, Patient, Policy, Pharmaceutical industry, Hikma

LONDON, Oct. 3, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of KLOXXADO® (naloxone HCl) nasal spray 8mg in the US – an important milestone in its ongoing work to help combat the opioid overdose epidemic.

Key Points:

With the help of more than 40 donation partners, KLOXXADO® has been distributed for free in places it can have the biggest impact, including music festivals, downtowns and schools.
"Since its launch two years ago, KLOXXADO® has quickly become an essential tool for those on the front lines working to reverse opioid overdoses and save lives," said Brian Hoffmann, President, Hikma Generics.
Furthering its partnership with Remedy Alliance through a first-of-its-kind agreement for Hikma to provide a private label, discounted naloxone injectable medicine specifically for the harm reduction community.
Ensuring widespread access to KLOXXADO® by providing a Co-Pay Assistance Program for eligible individuals, further increasing access and decreasing out-of-pocket costs to this life-saving medication.

Hikma completes acquisition of Custopharm

Retrieved on:

Thursday, April 21, 2022

Calcitonin, Achievement, ANDA, Federal Trade Commission, Hospital, Patient, Salmon, CGT, Hikma Pharmaceuticals, FDA, Acquisition, Water Street, Pharmaceutical industry, Hikma

LONDON, April 21, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has completed its acquisition of Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'), following approval from the US Federal Trade Commission.

Key Points:

LONDON, April 21, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC(Hikma),the multinational pharmaceutical company, today announces that it has completed its acquisition of Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'), following approval from the US Federal Trade Commission.
As previously announced on 27 September 2021, Hikma has acquired Custopharm for an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certain commercial milestones.
Hikma is the second-largest supplier by volume of generic sterile injectable medicines used by US hospitals and health care providers.
I am excited to welcome the team at Custopharm to Hikma as we continue to grow and strengthen our Injectables business."

Hikma Launches New 503B Sterile Compounding Business

Retrieved on:

Monday, January 10, 2022

Automation, CGMP, Philosophy, Patient, Physician, Hospital, Health, Hikma, FDA, Nursing, Pharmaceutical industry

LONDON, Jan. 10, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical company, announces the launch of Hikma 503B a new outsourced sterile compounding business focused on providing high quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.

Key Points:

LONDON, Jan. 10, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical company, announces the launch of Hikma 503B a new outsourced sterile compounding business focused on providing high quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.
"We are applying Hikma's expertise, talent, and engrained commitment to quality to ensure our 503B business meets CGMP standards, which is what the FDA requires of 503B outsourcing facilities," said Joel Rosenstack, Chief Commercial Officer, US Injectables, Hikma.
"Our 503B business is powered by the same team and philosophy that is behind Hikma's reputation for quality medicines."
Hikma 503B is registering for state licenses across the US and expects to be operating nationwide by the end of 2022.

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva®

Retrieved on:

Thursday, December 9, 2021

("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia and Xgeva("Products"), in the United States ("US").

Key Points:

("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia and Xgeva("Products"), in the United States ("US").
Hikma is responsible for registering the Products with the US Food and Drug Administration and will have exclusive rights to commercialise them in the US.
"We are looking forward to collaborating with Hikma on this important biosimilar project targeting the US market," said Gbor Orbn, Chief Executive Officer of Richter.
Denosumab is a RANKL inhibitor which works by preventing the development of osteoclasts, which are cells that break down bone.

Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)

Retrieved on:

Friday, August 27, 2021

Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara (ustekinumab), in the United States (US).

Key Points:

Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara (ustekinumab), in the United States (US).
Partnering with Hikma to commercialize BAT2206, our ustekinumab biosimilar, further validates the high quality of the work performed at Bio-Thera, said Dr. Shengfeng Li, CEO of Bio-Thera Solutions.
Tapping into the growth of the biosimilar market in the US has been an area of focus for Hikma.
2 QLETLI is a registered trademark of Bio-Thera Solutions, Ltd.
3 is a registered trademark of Bio-Thera Solutions, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005059/en/